(A) | 1. |
¤@¦ì30·³¨k©Ê±wªÌ¥D¶DG»Ä°f¬y¡A¯Ý°©«á¤è¦³¨`¼ö·P¡A¤U¦C¦óªÌ¤£·|¼W¥[¦¹¯fªº·ÀI©Î´c¤Æ¯f¤Hªº¯gª¬¡H
|
A. | «ÕªùÁ³±Û±ìµß(Helicobacter pylori)·P¬V |
B. | ©â·Ï |
C. | ªÎD |
D. | ¶tÂ÷¤l³q¹DªýÂ_¾¯(calcium channel blocker) |
E. | §tÁ¡²üÃþ¹ª« |
|
(D) | 2. |
¤U¦C¦óªÌ»P¹¹DÅ쪬¤W¥Ö²ÓMÀù(esophageal squamous cell carcinoma)ªºµo¥ÍµLÃö¡H
|
A. | ©â·Ï |
B. | ³Ü°s |
C. | ªø´Á³Ü¼ö¯ù |
D. | ¤Ú¬¥¤ó¹¹D(Barrett's esophagus) |
E. | ¹¹D¦¢½w¤£¯à(achalasia) |
|
(D) | 3. |
¤U¦C¦óªÌ¤£·|«P¶iG»Äªº¤Àªc
|
A. | histamine |
B. | acetylcholine |
C. | gastrin |
D. | somatostatin |
E. | ¨ë¿E°g¨«¯«¸g(vagus nerve) |
|
(B) | 4. |
¤U¦C¦³Ãö«ÕªùÁ³±Û±ìµß(Helicobacter pylori)ªº±Ôz¡A¦óªÌ¥¿½T?
1.80%·P¬VªÌ·|¦³®ø¤Æ©Ê¼ìºÅ¡A2.°£µß«á¬ù60-75%ªºGÂH½¤¬ÛÃö²O¤Ú²Õ´²O¤ÚÀù(mucosa-associated lymphoid tissue lymploma)¥i¥H±o¨ì½w¸Ñ¡A3.»PG¶NªùÀùµo¥Í¦³Ãö¡A4.ÄÝ©ó¨ã¦³§¿¯ÀúC(urease)¤§²Äõ¤ó³±©Êµß(Gram-negative bacteria)
|
A. | 1+3 |
B. | 2+4 |
C. | 1+4 |
D. | 3+4 |
E. | 1+2 |
|
(B) | 5. |
¤@¦ì¤Q¤G«ü¸z¼ìºÅªº±wªÌ¦b±µ¨ü®Ú°£«ÕªùÁ³±Û±ìµß(Helicobacter pylori)ªº¤T¦X¤@Àøªk¤§«á¡A¤U¦C¦ó¶µÀˬd³Ì¾A¦X¥Î©ó½T©w±þµß¦¨¥\»P§_?
|
A. | §Ö³t§¿¯ÀúC(rapid urease)´ú¸Õ |
B. | §¿¯À©I§lÀˬd(urea breath test) |
C. | ¦å²M¾Ç(serology)ÀË´ú |
D. | ¯f²z²Õ´Àˬd(histology) |
E. | ÁT«K§Üì(stool antigen)Àˬd |
|
(A) | 6. |
¤@¦ì®ø¤Æ©Ê¼ìºÅ±wªÌ¦]¥X¦å±µ¨ü³¡¥÷G¤Á°£¦X¨Ö°g¨«¯«¸gºIÂ_³N(subtotal gastrectomy & vagotomy)«á¡A¦b¶i¹90¤ÀÄÁ¦Ü180¤ÀÄÁ«á¦³®É·|¥X²{ÀYµh¡Bµs¦½¡B¤ß±ª¡A¬Æ¦Ü©ü˱¡§Î¡C¤U¦C¦ó¶µ³B¸mµL¯q©ó´î»´¦¹±wªÌªº¯gª¬¡H
|
A. | ¤Ö¦Yªo¯×¦h¦Y´I§tºÒ¤ô¤Æ¦Xª«ªº¹ª« |
B. | ¤Ö¶q¦hÀ\ |
C. | ÁקK¶i¹¤Ó¦h¬y½è¹ª« |
D. | µ¹¤©acarbose |
E. | Y§ïÅܶ¼¹¤è¦¡µL®ÄªÌ¡A«h¥iµ¹¤©octreotide |
|
(C) | 7. |
¤@¦ì30·³¤k©Ê±wªÌ¦³©úÅ㸡Âm¡B¤ô¸~(edema)²{¶H¡A¦í°|Àˬdµo²{albumin¡G1.4 g/dL globulin¡G1.6 g/dL¡A¨x¥Í¤ÆÀËÅçµ²ªG¥¿±`¡A§¿²G¤¤¨ÃµL³J¥Õ¡A¤p¸z¥ÍÀˤ§¯f²z³ø§i¬°intestinal lymphangiectasia¡C½Ð°Ý¤U¦C¦óºØ¶¼¹³B¤è¦³§Q©ó§ïµ½¦¹±wªÌªº¯gª¬¡H
|
A. | §C¶u¶¼¹ |
B. | °ª³J¥Õ¶¼¹ |
C. | §t¤¤Ãì¯×ªÕ»Ä(medium-chain triglycerides)§C¯×¶¼¹ |
D. | µLgluten¶¼¹(gluten-free diet) |
E. | °ª¶t¶¼¹ |
|
(A) | 8. |
µoª¢©Ê¤j¸z¯e¯f(inflammatory bowel disease)¥]§t¼ìºÅ©Ê¤j¸zª¢(ulcerative colitis)©M§J¶©¤ó¯g(Crohn's disease)¡A³oÃþ±wªÌ±`·|¦X¨Ö¸z¹D¥~ªí²{(extraintestinal manifestation)¡C¤U¦C¦ó¶µªí²{¦b¼ìºÅ©Ê¤j¸zª¢¸û§J¶©¤ó¯g§ó±`¨£¡H
|
A. | pyoderma gangrenosum |
B. | ankylosing spondylitis |
C. | nephrolithiasis |
D. | cholelithiasis |
E. | episcleritis |
|
(C) | 9. |
¤U¦C¦óªÌ¬°¤j¸zÀù(colon cancer)¤§¦MÀI¦]¤l?
1.°ª³J¥Õ¶¼¹
2.¯Ø®q¯Àªý§Ü(insulin resistance)
3.¤j¸z¿Eļ¯g(irritable bowel syndrome)
4.E. coli bacteremia
5.ureterosigmoidostomy
|
A. | 1+2 |
B. | 3+4 |
C. | 2+5 |
D. | 1+4 |
E. | 2+3 |
|
(E) | 10. |
Ãö©ó«DÃþ©T¾J§Üµoª¢ßÓª«¡]NSAID¡^¾ÉPªºG¸z¹D¨Öµo¯g¡A¤U¦C±Ôz¦óªÌ¿ù»~¡H
1. ÄY«ªºNSAID¾ÉPªº¨Öµo¯g¡A¤j¦h¼Æ¯f±w©ó¿©¯f«eÀ³¦³dyspepsia
2. §C¾¯¶q¡]<=75 mg/d¡^Aspirin¤£·|¾ÉPÄY«ªº¨Öµo¯g
3. ¦~¬ö¤j¡A¹L¥h¦³®ø¤Æ©Ê¼ìºÅ¡A¦P®ÉªA¥Î§tÃþ©T¾J¤§ßÓª«¡A¬Ò¬Oestablished risk factor
4. Y¦³risk factor¦Ó¤´»ÝªA¥ÎNSAID¡A¥i¥Hproton pump inhibitors©Îmisoprostol¹w¨¾G¸z¹D¨Öµo¯g
5. YNSAID¤w³y¦¨G¼ìºÅ¡A¦ý¤S¤£¯à°±¥Î¡A¥i¥ÎH2 blockerªvÀø
|
A. | 1 + 3 + 5 |
B. | 1 + 2 + 4 |
C. | 2 + 3 + 4 |
D. | 3 + 4 + 5 |
E. | 1 + 2 + 5 |
|
(C) | 11. |
¦³Ãöìµo©ÊÁx¹D©Ê¨xµw¤Æ (primary biliary cirrhosis) ¤§±Ôz¡A¦óªÌ¬°»~¡H(1) §Ü²É¸¢Åé§ÜÅé (AMA) ³q±`¶§©Ê(2) ¦nµo©ó¤k©Ê(3) ±`¦X¨Öµo¥Í©óºC©Ê¼ìºÅ©Êµ²¸zª¢±wªÌ(4) µoª¢©ÊÅÖºû¤Æ«I¥Ç¨x¤º¤Î¨x¥~ÁxºÞ(5) ERCP ©Î MRCP ¬°½T©w¶EÂ_¤è¦¡¡C(À³¿ï¥X¥þ³¡µª®×)
|
A. | 1 + 2 + 3 |
B. | 2 + 3 + 4 |
C. | 3 + 4 + 5 |
D. | 3 + 4 |
E. | 4 + 5 |
|
(E) | 12. |
¤@¦ì¯f¤H³QªB¤Í´£¿ô¥i¯à¦³¶À¯n²{¶H¡A´NÂå©â¦åÀËÅç¡Aµ²ªGBilirubin (Total) = 4.0 mg/dL¡C¤U¦C«áÄò³B¸m¡A¦óªÌ¨Ã«D³Ì¢¤Á»Ýn
|
A. | ¦A©â¦åÀËÅç Bilirubin (Direct) |
B. | ¦A©â¦åÀËÅç Prothrombin time (PT) |
C. | ¦A©â¦åÀËÅç Alkaline phosphatase (ALP)¤Îgamma-glutamyl transpeptidase (gamma-GT) |
D. | ¦A©â¦åÀËÅç ALT (GPT)¤ÎAST (GOT) |
E. | ¦A©â¦åÀËÅç Antinuclear antibody (ANA) |
|
(E) | 13. |
¤U¦C¦³Ãö¨xª¢¬Ì]ª`®g¤§´yz¡A¦óªÌ¿ù»~¡H
|
A. | ·s¥Í¨à®É´Á±µ¨ü¢Ð«¬¨xª¢¬Ì]ª`®g¥B²£¥Í¦³®Ä§ÜÅé (anti-HBs)¡A¬ù¦Ü²Ä¤Q¦~¥H«áÀ³ÀË´ú¨ä§ÜÅé¿@«×¬O§_¤w¤j´T°§C |
B. | ¦ÛµM·P¬V¦Ó²£¥Í¤§anti-HBs¡A40¦h·³®ÉYµo²{¤w®ø¥¢¡A¬én±µ¨ü¢Ð«¬¨xª¢¬Ì]ª`®g1~2¦¸¡]¶¡¹j¬ù¤@Ó¤ë¡^¡A§ÜÅé§Y¥i¦A«×¥X²{ |
C. | ¢Ï«¬¨xª¢¬Ì]»Ýnª`®g¨â¦¸¡A¶¡¹j¬ù¤»Ó¤ë¡ã¤@¦~ |
D. | ¢Ð«¬¨xª¢¬Ì]¦Ü¤Ö»Ýª`®g¤T¦¸¡A²Ä¤G¾¯»P²Ä¤@¾¯¬ù¶¡¹j¤@Ó¤ë¡A²Ä¤T¾¯»P²Ä¤G¾¯¬ù¶¡¹j¤Ó¤ë |
E. | Y«æ»Ýu¦³¢Ó«¬¨xª¢¦s¦b¤§¦a°Ï¡A¥i¦b¤@Ӥ뤧¤º±µ¨ü¨â¦¸¢Ó«¬¨xª¢¬Ì]ª`®g |
|
(A) | 14. |
¤U¦C¦U¶µ±Ôz¡A¦óªÌ¿ù»~¡H
|
A. | Wilson's disease±wªÌ¦å¤¤ceruloplasmin level·|²§±`¤É°ª |
B. | Wilson's disease±wªÌ§¿¤¤ªº»É±Æªn¶q·|²§±`¤É°ª |
C. | Wilson's disease©Ò¾ÉP¤§¨x°IºÜ±wªÌ¡A±µ¨ü¨xŦ²¾´Ó«á¥i²¬Â¡ |
D. | Hemochromatosis±wªÌ¦å¤¤fasting transferrin saturation³q±` > 100% |
E. | ¦å¤¤Ferritin¿@«×¦b¤@¨Çinflammatory disorders©Îneoplastic diseases¥ç·|²§±`¤É°ª |
|
(C) | 15. |
¤U¦C¦³Ãö¨xÅÖºû¤Æ¤§±Ôz¡A¦óªÌ¿ù»~¡H
|
A. | Hemochromatosis±wªÌ¦å¤¤ferritin > 1000 ug/L®É¡A¨ä¨x¤º±`¦³advanced fibrosis
|
B. | ¹ï°sºë©Ê¨x¯f±wªÌ¡A¥H¤âIJºN¨xŦ¤ñ¸¡³¡¶Wµªi±½´y¯à§óºë·Ç§PÂ_¨xµw¤Æ¤§¦³µL |
C. | Elastography (Fibro Scan)¥Ø«e¤w³Q¥Î¨Ó°»´ú¨x¤ºÅÖºû¤Æ¤§µ{«×¡A¦ý¤´¬Û·í¤£·Ç½T |
D. | ¨x¬ï¨ë¡]liver biopsy¡^¥Ø«e¤´¬O§PÂ_¨x¤ºÅÖºû¤Æ¦s¦b»P§_¤Î¨äµ{«×¤§reference standard |
E. | ¦å¤pªO¼Æ¶q¥i¥Î¨Ó§PÂ_ºC©Ê¨x¯f±wªÌ¬O§_¦³¨xÅÖºû¤Æ |
|
(D) | 16. |
ºC©Ê¯f¬r©Ê¨xª¢¬O¥xÆW¦a°Ï³Ì±`¨£¤§¨x¯f¡A¤U¦C¦³Ãö¨äªvÀø¤§±Ôz¡A¦óªÌ¿ù»~¡H
1. ºC©Ê¢Ñ«¬¨xª¢¥DnªvÀø¤è¦¡¬°Interferon + Ribavirin
2. ºC©Ê¢Ð«¬¨xª¢¤§ªvÀø¤è¦¡¦³Interferonª`®g¤Î¤fªA§Ü¢Ð«¬¨xª¢¯f¬rÃĪ«¨âºØ
3. Interferonª`®g¥i¯à²£¥Íµo¿N¡BÀYµh¡B¬Æ¦Ü¼~Æ{ (depression)¤§°Æ§@¥Î
4. Ribavirin¥i¯à¾ÉP¥Õ¦å²y¼Æ¥Ø¤U°
5. ³sÄòªA¥Î®É¡A¢Ð«¬¨xª¢¯f¬r¹ïEntecavir (¨©¼Ö§J¡ABaraclude)³Ì®e©ö²£¥Í§ÜÃÄ©Ê
|
A. | 1+2 |
B. | 2+3 |
C. | 3+4 |
D. | 4+5 |
E. | 5+1 |
|
(B) | 17. |
¤U¦C¦U¶µ±Ôz¡A¦óªÌ¥¿½T¡H
1. ºC©Ê¢Ñ«¬¨xª¢±wªÌ¡A¨C¤Ñ³Ü°s¶W¹L20-50 g¡A¾ÉP¨xµw¤Æ¤§·ÀI·|¼W¥[
2. ºC©Ê¢Ñ«¬¨xª¢±wªÌ¡A¨ä³Ü°s¶q»Pinterferon-based therapy¤§¦¨¥\²vµLÃö
3. ¨C¤Ñ³Ü°s¶W¹L20 g¡A¨k©Ê¸û©ö¿©±w°sºë©Ê¨x¯f
4. °sºë©Ê¨xª¢±wªÌ¤§¦å¤¤AST (GOT)/ALT (GPT)¤§¤ñȱ` > 1¡A¦ÓºC©Ê¯f¬r©Ê¨xª¢±wªÌ«h±` < 1
|
A. | 1+2 |
B. | 1+4 |
C. | 2+3 |
D. | 3+4 |
E. | 1+3 |
|
(D) | 18. |
¤@¦ì¨xµw¤Æ¯f¤H¦]´NÂå¤è«K©Ê¡A§Æ±æ¦b§Aªºªù¶E°lÂÜ¡C¥L¬OºC©Ê¢Ð«¬¨xª¢±wªÌ¡A¦b°lÂܹLµ{¤¤¡A§AÀ³¸Ó¬°¥L¦w±Æ¤U¦C¦U¶µÀËÅç©ÎÀˬd¡A¦óªÌ¿ù»~¡H
|
A. | ©w´Á©â¦åÀËÅçGOT (AST)¤ÎGPT (ALT) |
B. | ©w´Á©â¦åÀËÅç CBC¡A¥]§tPlatelet count |
C. | ©w´Á©â¦åÀËÅçProthrombin time (PT) |
D. | ¨C¨â¦~¦w±Æ¤@¦¸¸¡³¡¶WµªiÀˬd |
E. | Y¸¡³¡¶WµªiÀˬdµo²{¦³µÊ¸~¤j¡AÀ³«Øij¯f¤H±µ¨ü¤W®ø¤Æ¹D¤ºµøÃèÀˬd |
|
(E) | 19. |
¤U¦C¦U¶µ¬°±Á{¹x©TÃøªv¸¡¤ô (refractory ascite)®É¥²»Ý¦Ò¼{¤§¥i¯à³B¸m¡A°£¤F¡G
|
A. | TIPS (Transjugular Intrahepatic Porto-Systemic Shunt) |
B. | LVP (Large Volume Paracentesis) + albumin supply |
C. | ¨xŦ²¾´Ó |
D. | ¨îÆQ¤ÀÄá¨ú + §Q§¿¾¯ |
E. | Phlebotomy |
|
(C) | 20. |
Ãö©ó¨x²ÓMÀù¤§ªvÀø¡A¤U¦C¦óªÌ¥Ø«e©|«D¥D¬y¤è¦¡¡G
|
A. | ¶}¤M¤Á°£ (resection) |
B. | ¨x°Ê¯ß®ê¶ë (transhepatic arterial embolization, TAE) |
C. | ¼Ð¹vªvÀø (molecularly target therapy) |
D. | °sºëª`®g (percutaneous ethanol injection therapy)
|
E. | ®gÀW¿N¨`ªvÀø (radiofrequency ablation) |
|
(A) | 21. |
Ãö©ó¨xŦ²¾´Ó¡A¤U¦C±Ôz¦óªÌ¿ù»~¡H
|
A. | ¤â³N§¹¦¨3Ó¤ë¥H«á¡A¥¢±Ñªº¥D¦]¬°·P¬V¤Î¥X¦å¡C |
B. | ¬é¦³³¡¤Àªº¨xMÀù±wªÌ¯à±µ¨ü¨xŦ²¾´ÓªvÀø¡C |
C. | ÁxºÞ²ÓMÀù±wªÌµ´¹ï¤£¯à¥H¨xŦ²¾´Ó¤â³NªvÀø¤§¡C |
D. | ¢Ñ«¬¨xª¢¯f¬r¾ÉP¤§¨xµw¤Æ ±wªÌ¡A±µ¨ü¨xŦ²¾´Ó«á¡A¨ä¢Ñ«¬¨xª¢¤j¦h·|´_µo¡C |
E. | ìµo©ÊÁx¥Äº¢¯d©Ê¨xµw¤Æ (primary biliary cirrhosis) ±wªÌ¡A¨xŦ²¾´Ó¤§¦¨¥\²v«Ü°ª¡C |
|
(A) | 22. |
¯f¤H¦]«å¦Ó©â¦å¡A¨äµ²ªG¦p¤U¡GGOT=33 (< 37 IU/L)¡AGPT=37 (< 41 IU/L)¡ABil (T)=0.7 (< 1 mg/dL)¡AAlb=3.8 ( >3.5 g/dL)¡AGlobulin=8.0(< 3.5 g/dL)¡AALP=200 ( < 240 IU/L)¡Ar-GT=48 (< 50 IU/L)¡C¤U¦C¦U¶µ«áÄòÀˬd©ÎÀËÅç¡A¨º¨Ç¬O¦X²zªº¡H
1. abdominal ultrasound
2. MRI (magnetic resonance image)
3. serum protein electrophoresis
4. antimitochondrial antibody (AMA)
5. urine protein electrophoriesis
6. bone scan
|
A. | 1+3+5 |
B. | 2+3+4 |
C. | 3+4+6 |
D. | 2+4+5 |
E. | 1+5+6 |
|